Rua Bioscience (NZX: RUA) today released its Annual Report for the 12 months ended 30 June 2022 (FY22).
In our Annual Report, we review the strides Rua Bioscience has made in the past 12 months, outline our current performance and share our aspirations for the future. We’ll give you insight into our industry and the ever-changing environment within which we operate as an ambitious medicinal cannabis start-up. We’ll also explore our deep connection to Te Tairāwhiti and the responsibilities we carry as a company established to have a positive impact on our people and our whenua.
The Annual Report is attached and available now on the Rua website www.ruabio.com/investors. Those who have requested it will receive a hard copy in the post in due course.
ENDS
For more information, please visit www.ruabio.com or contact:
Investors
Hamish White
Chief Financial Officer
+64 (21) 050 5795
[email protected]
Media
Kerry Donovan
Communications Manager
+64 (21) 128 7689
[email protected]
The S&P/NZX 50 Index closed at 12,266.25, gaining 57.2 points or 0.47%.
Goldman Sach analysts have a 12-month target price of A$2.85 ($3.14).
An investment firm bought the stake, which included 116,145 hectares of forestry.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details